A Phase 3 interventional study of obinutuzumab and rituximab in Lymphocytic Leukemia, Chronic, sponsored by Hoffmann-La Roche. Completed at 262 sites in 26 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-09-14.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies testing obinutuzumab in Leukemia, Lymphocytic, Chronic, B-Cell — 16 open to participants now, 28 under way, 6 of them phase 3. obinutuzumab · Leukemia, Lymphocytic, Chronic, B-Cell.
Among the 53 studies testing obinutuzumab in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 4th largest by enrollment, is one of 3 that started in 2009, is one of 13 in phase 3, and was the 1st registered.
2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →16 of the 53 studies testing obinutuzumab in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
BeOne Medicines · Sites in United States, Argentina, Australia and 18 more countries
Ages 18+
PETHEMA Foundation · Sites in Spain
Ages 18+
AbbVie · Sites in United States, Australia, France and 6 more countries
Ages 18+
By country, each count listing its studies:
obinutuzumab: first FDA approval 2013 (GAZYVA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 188 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 32 · Phase 3 13
First in 2009; this study’s year is marked. 3 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 787 is above the median of 39 across 1,603 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Median enrollment 72 across the 53 interventional studies. Of the 22 that completed or were terminated, 14 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 53 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
48 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Hoffmann-La Roche: 1 open now, 2 under way, none of them phase 3. Of 46 finished, 28 (61%) have results posted.
Among the 48 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Hoffmann-La Roche, this one is the 3rd largest by enrollment of the 36 interventional ones that give a count, is one of 6 that started in 2009, is one of 10 in phase 3, and was the 9th registered.
Hoffmann-La Roche’s Leukemia, Lymphocytic, Chronic, B-Cell studies by the year they started, since 2003.
12 of the studies testing obinutuzumab in Leukemia, Lymphocytic, Chronic, B-Cell that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03836261Phase 3Acerta Pharma BVStudy of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL | 2027-04-30 |
| NCT05057494Phase 3AstraZenecaA Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | 2027-07-15 |
| NCT04895436AbbVieStudy to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) | 2026-11 |
| NCT05943496OHSU Knight Cancer InstituteTafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | 2027-01-01 |
| NCT04722172Memorial Sloan Kettering Cancer CenterA Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL | 2027-02 |
Add all 12 to your calendar (.ics) → With an account.
Among the 53 studies testing obinutuzumab in Leukemia, Lymphocytic, Chronic, B-Cell, from their registry updates:
Among Hoffmann-La Roche’s 48 in Leukemia, Lymphocytic, Chronic, B-Cell:
This tab as a report to print or save as PDF → With an account.
This open-label, randomized, 3-arm study will evaluate the efficacy and safety of obinutuzumab (RO5072759) in combination with chlorambucil as compared to rituximab plus chlorambucil or chlorambucil alone in patients with previously untreated chronic lymphocytic leukemia (CLL). Patients will be randomized 2:2:1 to receive a maximum of six 28-day cycles of either RO5072759 (1000 mg intravenous (iv) infusion, on days 1, 8 and 15 of cycle 1 and day 1 of cycles 2-6) plus chlorambucil (0.5 mg/kg orally, days 1 and 15 of cycles 1-6), or rituximab (iv infusion day 1, 375 mg/m\^2 cycle 1, 500 mg/m\^2 cycles 2-6) plus chlorambucil, or chlorambucil alone. Anticipated time on study treatment is >6 months and follow-up for disease-progression and safety will be at least 5 years. In the US, this trial is sponsored/managed by Genentech.
Protocol BO21004 is divided into 3 separate Unique Protocol IDs for reporting results on clinicaltrials.gov because there are 3 separate primary analyses conducted at different time-points.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 \[first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment\], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles) plus chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles).
Drug: obinutuzumab · Drug: chlorambucil
Participants received 375 mg/m\^2 rituximab IV infusion on Day 1 of Cycle 1 then 500 mg/m\^2 IV infusions on Day 1 of Cycles 2-6 (28-day cycles) plus chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 cycles).
Drug: rituximab · Drug: chlorambucil
Participants received chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles). Participants with Progressive Disease or within 6 months of follow-up were allowed to cross over to receive obinutuzumab + chlorambucil.
Drug: chlorambucil
1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 \[first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment\], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles).
Also known as: RO5072759, GA101, GAZYVA®
375 mg/m\^2 rituximab intravenous (IV) infusion on Day 1 of Cycle 1 (Cycle duration is 28 days) then 500 mg/m\^2 IV infusions on Day 1 of Cycles 2-6.
Also known as: Rituxan®, MabThera®
Chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle.
Progression-free Survival (PFS)
PFS was defined as the time from randomization to the first occurrence of progression, relapse, or death from any cause as assessed by the investigator. Progressive disease (PD) required at least one of the following: ≥50% increase in the absolute number of lymphocytes, appearance of new palpable lymph nodes (\>15 mm in longest diameter) or any new extra nodal lesion, ≥50% increase in the longest diameter of any previous site of clinically significant lymphadenopathy, ≥50% increase in the enlargement of the liver and/or spleen, Transformation to a more aggressive histology or After treatment, the progression of any cytopenia (a decrease of hemoglobin levels \>20 g/L or \<10 g/dL or a decrease of platelet counts \>50% or \<100 x 10\^9/L or by a decrease of neutrophil counts \>50% or \<1.0 x 10\^9/L).
Time frame: Randomization to clinical cutoff date of 10 Oct 2017 (median observation 62.5 months from randomization)
Percentage of Participants With Progression Free Survival Events
Percentage of Participants with Progression Free Survival Events: disease progression, relapse, or death.
Time frame: Randomization to clinical cutoff date of 10 Oct 2017 (median observation 62.5 months from randomization)
Progression Free Survival Based on Independent Review Committee (IRC) Data
PFS was defined as the time from randomization to the first occurrence of progression, relapse, or death from any cause as assessed by Independent Review Committee. Progressive disease required at least one of the following: ≥50% increase in the absolute number of lymphocytes, appearance of new palpable lymph nodes (\>15 mm in longest diameter) or any new extra nodal lesion, ≥50% increase in the longest diameter of any previous site of clinically significant lymphadenopathy, ≥50% increase in the enlargement of the liver and/or spleen, Transformation to a more aggressive histology or After treatment, the progression of any cytopenia (a decrease of hemoglobin levels \>20 g/L or \<10 g/dL or a decrease of platelet counts \>50% or \<100 x 10\^9/L or by a decrease of neutrophil counts \>50% or \<1.0 x 10\^9/L).
Time frame: Randomization to clinical cutoff date of 9 May 2013 (median observation 22.8 months)
Percentage of Participants With Progression Free Survival Events Based on Independent Review Committee (IRC) Data
Percentage of Participants with Progression Free Survival Events: progression, relapse, or death from any cause as assessed by an Independent Review Committee.
Time frame: Randomization to clinical cutoff date of 9 May 2013 (median observation 22.8 months)
Percentage of Participants With End of Treatment Response (EOTR)
EOTR was the first response assessment 56 days from the last dose according to the International Workshop on Chronic Lymphocytic Leukaemia (IWCLL) guidelines. CR required: Peripheral blood lymphocytes below 4 x 10\^9/L, Absence of significant lymphadenopathy, No hepatomegaly, No splenomegaly, Absence of disease, Blood counts above the following values (Neutrophils \>1.5 x 10\^9/L, Platelets \>100 x 10\^9/L, Hemoglobin \>11g/dL) and Bone marrow at least normocellular for age. CRi was CR with incomplete bone marrow recovery. PR required the following for at least 2 months from end of treatment: ≥50% decrease in peripheral blood lymphocyte count from the pre-treatment value AND Either a ≥ 50% reduction in lymphadenopathy OR ≥50% reduction of liver enlargement OR ≥50% reduction of spleen enlargement PLUS at least one of the following: Neutrophils \>1.5 x 10\^9/ or ≥50% increase, Platelets \>100 x 10\^9/L or ≥50% increase, Hemoglobin 11 g/dL or ≥50% increase.
Time frame: Randomization to clinical cutoff date of 10 Oct 2017 (median observation 62.5 months from randomization)
Percentage of Participants With Best Overall Response
Best overall response according to IWCLL guidelines was defined as the percentage of patients with CR, CRi,PR or nPR. CR required all of the following: Peripheral blood lymphocytes below 4 x 10\^9/L, Absence of significant lymphadenopathy, No hepatomegaly, No splenomegaly, Absence of disease, Blood counts above the following values (Neutrophils \>1.5 x 10\^9/L, Platelets \>100 x 10\^9/L, Hemoglobin \>11g/dL) and Bone marrow at least normocellular for age. CRi was CR with incomplete bone marrow recovery. PR required the following for at least 2 months from end of treatment: ≥50% decrease in peripheral blood lymphocyte count from the pre-treatment value AND Either a ≥ 50% reduction in lymphadenopathy OR ≥50% reduction of liver enlargement OR ≥50% reduction of spleen enlargement PLUS at least one of the following: Neutrophils \>1.5 x 10\^9/ or ≥50% increase, Platelets \>100 x 10\^9/L or ≥50% increase, Hemoglobin 11 g/dL or ≥50% increase.
Time frame: Randomization to clinical cutoff date of 10 Oct 2017 (median observation 62.5 months from randomization)
Event Free Survival
Event-free survival (EFS) was defined as the time between date of randomization and the date of disease progression/relapse, death, or start of a new anti-leukemic therapy. Progressive disease as per IWCLL criteria required at least one of the following: ≥50% increase in the absolute number of lymphocytes, appearance of new palpable lymph nodes (\>15 mm in longest diameter) or any new extra nodal lesion, ≥50% increase in the longest diameter of any previous site of clinically significant lymphadenopathy, ≥50% increase in the enlargement of the liver and/or spleen, Transformation to a more aggressive histology or After treatment, the progression of any cytopenia (a decrease of hemoglobin levels \>20 g/L or \<10 g/dL or a decrease of platelet counts \>50% or \<100 x 10\^9/L or by a decrease of neutrophil counts \>50% or \<1.0 x 10\^9/L).
Time frame: Randomization to clinical cutoff date of 10 Oct 2017 (median observation 62.5 months from randomization)
Overall Survival
Overall Survival (OS) was defined as the time between the date of randomization and the date of death due to any cause.
Time frame: Randomization to clinical cutoff date of 10 Oct 2017 (median observation 62.5 months from randomization)
Duration of Response
Duration of Response was defined as the date the response \[either Complete Response (CR) or Partial Response (PR)\] was first recorded until the date of Disease Progression or death due to any cause. Response was assessed according IWCLL guidelines.
Time frame: Randomization to clinical cutoff date of 10 Oct 2017 (median observation 62.5 months from randomization)
Percentage of Participants With Molecular Remission at the End of Treatment
Molecular remission was defined as a minimal residual disease (MRD)-negative result at the end of treatment (assessment that occurred between 56 days and 6 months of last treatment). Molecular remission was assessed for all patients using a blood sample. Additionally, a bone marrow sample was obtained from patients whom the investigator assumed to have a complete response, consistent with the IWCLL guidelines. A combined analysis of blood and bone marrow results was conducted. A patient was considered MRD negative if result was less than 1 chronic lymphocytic leukemia (CLL) cell in 10000 leukocytes (MRD value \< 0.0001) based on the method of allele specific polymerase chain reaction (ASO-PCR).
Time frame: Randomization to clinical cutoff date of 10 Oct 2017 (median observation 62.5 months from randomization)
Time to Re-Treatment/New-antileukemic Therapy
Time to re-treatment/new anti-leukemic therapy was defined as time between the date of randomization and the date of first intake of re-treatment or new anti-leukemic therapy.
Time frame: Randomization to clinical cutoff date of 10 Oct 2017 (median observation 62.5 months from randomization)
Pharmacokinetics of Obinutuzumab (RO5072759) in Combination With Chlorambucil (Clb)
Blood samples were collected from all patients allocated to the GClb treatment arm pre- and post-dose Day 1 of Cycles 1 to 6 and were sent to a laboratory. The concentration of obinutzumab in serum was determined using a validated enzyme-linked immunosorbent assay (ELISA) and was reported in micrograms/milliliter (μg/mL).
Time frame: Pre- and post-dose sampling on day 1 of cycles 1-6 (Up to 26.8 months)
European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 Questionnaire Score
The EORTC Quality of Life Questionnaire QLQ-C30 was used to assess patient-reported outcomes (PRO) and symptom burden. The QLQ-C30 contains 30 items including the functional scales of physical functioning (5 items), role functioning (2 items), emotional functioning (4 items), cognitive functioning (2 items), social functioning (2 items) and symptom scales including fatigue (3 items), nausea and vomiting (2 items), and pain (4 items) and six single item scales on dyspnea, sleep disturbance, appetite loss, constipation, diarrhea and financial impact. Final scores are transformed such that they range from 0 - 100, whereby higher scores indicate greater functioning, greater quality of life, or a greater degree of symptoms, with changes of 5 - 10 points considered to be of minimally important difference to participants. A positive change from Baseline indicated improvement.
Time frame: Baseline and Cycle 4 Day 1 (Cy4D1)
European Organization for Research and Treatment of Cancer (EORTC) QLQ-CLL16 Questionnaire Score
EORTC Quality of Life Questionnaire (QLQ-CLL16) module was used to assess patient-reported outcomes and symptom burden. The QLQ-CLL16 module includes three multi-item scales assessing fatigue (2 items), treatment side effects and disease symptoms (8 items), infection (4 items) and two single item scales on social activities and future health worries. Final scores are transformed such that they range from 0 - 100, whereby higher scores indicate greater functioning, greater quality of life, or a greater degree of symptoms, with changes of 5 - 10 points considered to be of minimally important difference to participants. A positive change from Baseline indicated improvement.
Time frame: Baseline and Cycle 4 Day 1 (Cy4D1)
787 patients were enrolled in the study. Following a 6 patient safety run-in prior to randomization, 781 patients were randomized.
| Milestone | Obinutuzumab + Chlorambucil (GClb) | Chlorambucil (Clb) |
|---|---|---|
| Started | 238 | 118 |
| Received study drug | 236 | 116 |
| Completed | 190 | 78 |
| Not completed | 48 | 40 |
| Withdrew: Adverse events or intercurrent illness | 33 | 16 |
| Withdrew: Disease progression | 2 | 8 |
| Withdrew: Withdrew consent | 5 | 1 |
| Withdrew: Death | 3 | 6 |
| Withdrew: Administrative/other | 0 | 1 |
| Withdrew: Refused treatment/did not cooperate | 2 | 0 |
| Withdrew: Insufficient therapeutic response | 1 | 5 |
| Withdrew: Violation of selection criteria | 0 | 1 |
| Withdrew: Did not receive treatment | 2 | 2 |
PFS was defined as the time from randomization to the first occurrence of progression, relapse, or death from any cause as assessed by the investigator. Progressive disease (PD) required at least one of the following: ≥50% increase in the absolute number of lymphocytes, appearance of new palpable lymph nodes (\>15 mm in longest diameter) or any new extra nodal lesion, ≥50% increase in the longest diameter of any previous site of clinically significant lymphadenopathy, ≥50% increase in the enlargement of the liver and/or spleen, Transformation to a more aggressive histology or After treatment, the progression of any cytopenia (a decrease of hemoglobin levels \>20 g/L or \<10 g/dL or a decrease of platelet counts \>50% or \<100 x 10\^9/L or by a decrease of neutrophil counts \>50% or \<1.0 x 10\^9/L).
| Months | Obinutuzumab + Chlorambucil (GClb) | Chlorambucil (Clb) |
|---|---|---|
| Progression-free Survival (PFS) | 31.1 (26.5 to 35.6) | 11.1 (10.7 to 11.3) |
Percentage of Participants with Progression Free Survival Events: disease progression, relapse, or death.
| Percentage of participants | Obinutuzumab + Chlorambucil (GClb) | Chlorambucil (Clb) |
|---|---|---|
| Percentage of Participants With Progression Free Survival Events | 72.7 | 90.7 |
PFS was defined as the time from randomization to the first occurrence of progression, relapse, or death from any cause as assessed by Independent Review Committee. Progressive disease required at least one of the following: ≥50% increase in the absolute number of lymphocytes, appearance of new palpable lymph nodes (\>15 mm in longest diameter) or any new extra nodal lesion, ≥50% increase in the longest diameter of any previous site of clinically significant lymphadenopathy, ≥50% increase in the enlargement of the liver and/or spleen, Transformation to a more aggressive histology or After treatment, the progression of any cytopenia (a decrease of hemoglobin levels \>20 g/L or \<10 g/dL or a decrease of platelet counts \>50% or \<100 x 10\^9/L or by a decrease of neutrophil counts \>50% or \<1.0 x 10\^9/L).
| Months | Obinutuzumab + Chlorambucil (GClb) | Chlorambucil (Clb) |
|---|---|---|
| Progression Free Survival Based on Independent Review Committee (IRC) Data | 27.2 (23.5 to 33.0) | 11.2 (11.0 to 12.1) |
Percentage of Participants with Progression Free Survival Events: progression, relapse, or death from any cause as assessed by an Independent Review Committee.
| Percentage of participants | Obinutuzumab + Chlorambucil (GClb) | Chlorambucil (Clb) |
|---|---|---|
| Percentage of Participants With Progression Free Survival Events Based on Independent Review Committee (IRC) Data | 37.4 | 76.3 |
EOTR was the first response assessment 56 days from the last dose according to the International Workshop on Chronic Lymphocytic Leukaemia (IWCLL) guidelines. CR required: Peripheral blood lymphocytes below 4 x 10\^9/L, Absence of significant lymphadenopathy, No hepatomegaly, No splenomegaly, Absence of disease, Blood counts above the following values (Neutrophils \>1.5 x 10\^9/L, Platelets \>100 x 10\^9/L, Hemoglobin \>11g/dL) and Bone marrow at least normocellular for age. CRi was CR with incomplete bone marrow recovery. PR required the following for at least 2 months from end of treatment: ≥50% decrease in peripheral blood lymphocyte count from the pre-treatment value AND Either a ≥ 50% reduction in lymphadenopathy OR ≥50% reduction of liver enlargement OR ≥50% reduction of spleen enlargement PLUS at least one of the following: Neutrophils \>1.5 x 10\^9/ or ≥50% increase, Platelets \>100 x 10\^9/L or ≥50% increase, Hemoglobin 11 g/dL or ≥50% increase.
| Percentage of participants | Obinutuzumab + Chlorambucil (GClb) | Chlorambucil (Clb) |
|---|---|---|
| Complete Response (CR) | 17.2 (12.7 to 22.6) | 0.0 (0.0 to 3.1) |
| Complete Response incomplete (CRi) | 4.2 (2 to 7.6) | 0.0 (0.0 to 3.1) |
| Partial Response (PR) | 48.3 (41.8 to 54.9) | 28.8 (20.8 to 37.9) |
| Nodular Partial Response (nPR) | 7.6 (4.5 to 11.7) | 2.5 (0.5 to 7.3) |
| Stable Disease | 5 (2.6 to 8.6) | 22.9 (15.7 to 31.5) |
| Progressive Disease | 4.2 (2.0 to 7.6) | 28.8 (20.8 to 37.9) |
| No Response Assessment | 13.4 (NA to NA) | 16.9 (NA to NA) |
Best overall response according to IWCLL guidelines was defined as the percentage of patients with CR, CRi,PR or nPR. CR required all of the following: Peripheral blood lymphocytes below 4 x 10\^9/L, Absence of significant lymphadenopathy, No hepatomegaly, No splenomegaly, Absence of disease, Blood counts above the following values (Neutrophils \>1.5 x 10\^9/L, Platelets \>100 x 10\^9/L, Hemoglobin \>11g/dL) and Bone marrow at least normocellular for age. CRi was CR with incomplete bone marrow recovery. PR required the following for at least 2 months from end of treatment: ≥50% decrease in peripheral blood lymphocyte count from the pre-treatment value AND Either a ≥ 50% reduction in lymphadenopathy OR ≥50% reduction of liver enlargement OR ≥50% reduction of spleen enlargement PLUS at least one of the following: Neutrophils \>1.5 x 10\^9/ or ≥50% increase, Platelets \>100 x 10\^9/L or ≥50% increase, Hemoglobin 11 g/dL or ≥50% increase.
| Percentage of participants | Obinutuzumab + Chlorambucil (GClb) | Chlorambucil (Clb) |
|---|---|---|
| Complete Response (CR) | 26.5 (21.0 to 32.6) | 0.0 (0 to 3.1) |
| Complete Response incomplete (CRi) | 2.5 (0.9 to 5.4) | 1.7 (0.2 to 6) |
| Partial Response (PR) | 47.1 (40.6 to 53.6) | 31.4 (23.1 to 40.5) |
| Nodular Partial Response (nPR) | 2.1 (0.7 to 4.8) | 0 (0 to 3.1) |
| Stable Disease | 4.2 (2 to 7.6) | 21.2 (14.2 to 29.7) |
| Progressive Disease | 4.2 (2.0 to 7.6) | 28.8 (20.8 to 37.9) |
| No Response Assessment | 13.4 (NA to NA) | 16.9 (NA to NA) |
Event-free survival (EFS) was defined as the time between date of randomization and the date of disease progression/relapse, death, or start of a new anti-leukemic therapy. Progressive disease as per IWCLL criteria required at least one of the following: ≥50% increase in the absolute number of lymphocytes, appearance of new palpable lymph nodes (\>15 mm in longest diameter) or any new extra nodal lesion, ≥50% increase in the longest diameter of any previous site of clinically significant lymphadenopathy, ≥50% increase in the enlargement of the liver and/or spleen, Transformation to a more aggressive histology or After treatment, the progression of any cytopenia (a decrease of hemoglobin levels \>20 g/L or \<10 g/dL or a decrease of platelet counts \>50% or \<100 x 10\^9/L or by a decrease of neutrophil counts \>50% or \<1.0 x 10\^9/L).
| Months | Obinutuzumab + Chlorambucil (GClb) | Chlorambucil (Clb) |
|---|---|---|
| Event Free Survival | 28.7 (23.9 to 32.9) | 10.8 (8.0 to 11.1) |
Overall Survival (OS) was defined as the time between the date of randomization and the date of death due to any cause.
| Months | Obinutuzumab + Chlorambucil (GClb) | Chlorambucil (Clb) |
|---|---|---|
| Overall Survival | NA (74.2 to NA) | 66.7 (50.9 to NA) |
Duration of Response was defined as the date the response \[either Complete Response (CR) or Partial Response (PR)\] was first recorded until the date of Disease Progression or death due to any cause. Response was assessed according IWCLL guidelines.
| Months | Obinutuzumab + Chlorambucil (GClb) | Chlorambucil (Clb) |
|---|---|---|
| Duration of Response | 24.8 (22.1 to 33.5) | 5.1 (3.3 to 6.7) |
Molecular remission was defined as a minimal residual disease (MRD)-negative result at the end of treatment (assessment that occurred between 56 days and 6 months of last treatment). Molecular remission was assessed for all patients using a blood sample. Additionally, a bone marrow sample was obtained from patients whom the investigator assumed to have a complete response, consistent with the IWCLL guidelines. A combined analysis of blood and bone marrow results was conducted. A patient was considered MRD negative if result was less than 1 chronic lymphocytic leukemia (CLL) cell in 10000 leukocytes (MRD value \< 0.0001) based on the method of allele specific polymerase chain reaction (ASO-PCR).
| Percentage of participants | Obinutuzumab + Chlorambucil (GClb) | Chlorambucil (Clb) |
|---|---|---|
| Percentage of Participants With Molecular Remission at the End of Treatment | 25 (18.9 to 32.6) | 0 (0.0 to 4.0) |
Time to re-treatment/new anti-leukemic therapy was defined as time between the date of randomization and the date of first intake of re-treatment or new anti-leukemic therapy.
| Months | Obinutuzumab + Chlorambucil (GClb) | Chlorambucil (Clb) |
|---|---|---|
| Time to Re-Treatment/New-antileukemic Therapy | 55.7 (47.4 to NA) | 15.1 (11.7 to 18.0) |
Blood samples were collected from all patients allocated to the GClb treatment arm pre- and post-dose Day 1 of Cycles 1 to 6 and were sent to a laboratory. The concentration of obinutzumab in serum was determined using a validated enzyme-linked immunosorbent assay (ELISA) and was reported in micrograms/milliliter (μg/mL).
| μg/mL | Obinutuzumab + Chlorambucil (GClb) |
|---|---|
| Post-dose Cycle 1 (n=201) | 247 ± 41.6 |
| Pre-dose Cycle 2 (n=198) | 227 ± 57.9 |
| Post-dose Cycle 2 (n=197) | 587 ± 36.5 |
| Pre-dose Cycle 3 (n=193) | 165 ± 68.7 |
| Post-dose Cycle 3 (n=192) | 527 ± 39.7 |
| Pre-dose Cycle 4 (n=191) | 156 ± 74.3 |
| Post-dose Cycle 4 (n=189) | 535 ± 41.0 |
| Pre-dose Cycle 5 (n=185) | 163 ± 72.4 |
| Post-dose Cycle 5 (n=181) | 534 ± 39.1 |
| Pre-dose Cycle 6 (n=185) | 181 ± 69.0 |
| Post-dose Cycle 6 (n=183) | 525 ± 39.6 |
The EORTC Quality of Life Questionnaire QLQ-C30 was used to assess patient-reported outcomes (PRO) and symptom burden. The QLQ-C30 contains 30 items including the functional scales of physical functioning (5 items), role functioning (2 items), emotional functioning (4 items), cognitive functioning (2 items), social functioning (2 items) and symptom scales including fatigue (3 items), nausea and vomiting (2 items), and pain (4 items) and six single item scales on dyspnea, sleep disturbance, appetite loss, constipation, diarrhea and financial impact. Final scores are transformed such that they range from 0 - 100, whereby higher scores indicate greater functioning, greater quality of life, or a greater degree of symptoms, with changes of 5 - 10 points considered to be of minimally important difference to participants. A positive change from Baseline indicated improvement.
| unit on a scale | Obinutuzumab + Chlorambucil (GClb) | Chlorambucil (Clb) |
|---|---|---|
| Appetite Loss Scale: Baseline (n=226, 111) | 18.1 ± 28.46 | 19.8 ± 29.26 |
| Appetite Loss Scale: Cy4D1 (n=189, 92) | 10.2 ± 21.77 | 14.5 ± 24.36 |
| Cognitive Functioning Scale: Baseline (n=227, 111) | 80.6 ± 21.35 | 81.8 ± 22.76 |
| Cognitive Functioning Scale:Cy4D1 (n=190,93) | 83.9 ± 20.31 | 85.8 ± 18.54 |
| Constipation Scale: Baseline (n=225, 111) | 14.8 ± 23.94 | 16.8 ± 26.92 |
| Constipation Scale: Cy4D1 (n=188, 93) | 15.1 ± 25.16 | 12.5 ± 23.53 |
| Diarrhoea Scale: Baseline (n=226, 110) | 9.3 ± 20.05 | 8.8 ± 18.98 |
| Diarrhoea Scale: Cy4D1 (n=189, 93) | 9.3 ± 19.47 | 6.5 ± 14.95 |
| Dyspnoea Scale: Baseline (n=225, 109) | 27.1 ± 29.89 | 23.9 ± 27.63 |
| Dyspnoea: Cy4D1 (n=189, 91) | 15.9 ± 23.71 | 22.3 ± 26.78 |
| Emotional Functioning Scale: Baseline (n=226, 111) | 73.8 ± 23.45 | 72.9 ± 25.7 |
| Emotional Functioning Scale: Cy4D1(n=190,93) | 82.5 ± 18.62 | 80.6 ± 18.48 |
| Fatigue Scale: Baseline (n=226, 111) | 38 ± 25.72 | 36.9 ± 27.01 |
| Fatigue Scale: Cy4D1(n=189, 93) | 29.2 ± 20.39 | 30.8 ± 23.00 |
| Financial Difficulties Scale: Baseline (n=224,110) | 8.9 ± 20.69 | 13.6 ± 25.26 |
| Financial Difficulty Scale: Cy4D1(n=189,93) | 7.4 ± 17.64 | 9.3 ± 19.88 |
| Nausea, Vomiting Scale: Baseline (n=227, 111) | 5 ± 11.18 | 7.4 ± 18.49 |
| Nausea, Vomiting Scale: Cy4D1 (n=189,93) | 5.5 ± 11.51 | 7.5 ± 17.81 |
| Pain scale: Baseline (n=228, 111) | 22.9 ± 27.57 | 21.5 ± 25.66 |
| Pain scale: Cy4D1 (n=190, 93) | 17.9 ± 24.09 | 17.7 ± 25.98 |
| Physical Functioning Scale: Baseline (n=228, 111) | 73.7 ± 19.86 | 77.3 ± 18.87 |
| Physical Functioning Scale: Cy4D1(n=189,93) | 78.6 ± 18.71 | 80.9 ± 16.24 |
| Global Health Status Scale: Baseline (n=226, 111) | 58.4 ± 22.8 | 57.4 ± 22.9 |
| Global Health Status Scale: Cy4D1(n=189,93) | 66.7 ± 20.03 | 63.4 ± 20.56 |
| Role Functioning Scale: Baseline(n=227,110) | 76.1 ± 26.18 | 74.7 ± 28.35 |
| Role Functioning Scale: Cy4D1(n=189,93) | 79.7 ± 23.64 | 81.5 ± 21.35 |
| Social Functioning Scale:Baseline(n=226,110) | 86.3 ± 22.52 | 83.3 ± 25.34 |
| Social Functioning Scale: Cy4D1(n=190,93) | 87.8 ± 19.97 | 85.5 ± 19.38 |
| Insomnia Scale: Baseline (n=228,111) | 29.4 ± 31.12 | 31.5 ± 32.98 |
| Insomnia Scale: Cy4D1(n=189,93) | 20.6 ± 27.13 | 24.4 ± 29.13 |
EORTC Quality of Life Questionnaire (QLQ-CLL16) module was used to assess patient-reported outcomes and symptom burden. The QLQ-CLL16 module includes three multi-item scales assessing fatigue (2 items), treatment side effects and disease symptoms (8 items), infection (4 items) and two single item scales on social activities and future health worries. Final scores are transformed such that they range from 0 - 100, whereby higher scores indicate greater functioning, greater quality of life, or a greater degree of symptoms, with changes of 5 - 10 points considered to be of minimally important difference to participants. A positive change from Baseline indicated improvement.
| unit on a scale | Obinutuzumab + Chlorambucil (GClb) | Chlorambucil (Clb) |
|---|---|---|
| Disease Effects Scale: Baseline (n=209, 102) | 23 ± 18.89 | 23.7 ± 20.18 |
| Disease Effects Scale: Cy4D1 (n=176, 86) | 15.0 ± 15.12 | 15.9 ± 14.16 |
| Fatigue Scale: Baseline (n=209, 102) | 31.2 ± 25.83 | 27.6 ± 24.65 |
| Fatigue Scale: Cy4D1 (n=176, 86) | 20.9 ± 21.51 | 23.4 ± 22.20 |
| Future Health: Baseline (n=206, 101) | 47.7 ± 32.14 | 50.8 ± 33.53 |
| Future Health: Cy4D1 (n=175, 86) | 29.5 ± 31.74 | 39.1 ± 30.33 |
| Infection Scale: Baseline (n=209, 102) | 12 ± 15.91 | 14.6 ± 17.97 |
| Infection Scale: Cy4D1 (n=176, 86) | 8.9 ± 11.65 | 8.5 ± 10.70 |
| Social Problems: Baseline (n=206, 100) | 24.3 ± 31.99 | 26.3 ± 33.26 |
| Social Problems: Cy4D1 (n=175, 85) | 19.4 ± 27.75 | 22.0 ± 27.00 |
| Treatment Side Effects Scale: Baseline (n=209,102) | 19.8 ± 17.7 | 17.2 ± 15.27 |
| Treatment Side Effect Scale: Cy4D1(n=176,86) | 14.7 ± 14.68 | 15.6 ± 16.11 |
Collected over Randomization to clinical cutoff (median observation 42 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Obinutuzumab + Chlorambucil (GClb) | — | 113/241 (46.9%) | 215/241 (89.2%) |
| Chlorambucil (Clb) | — | 45/116 (38.8%) | 89/116 (76.7%) |
| Crossover Subjects: Obinutuzumab + Chlorambucil (GClb) | — | 8/30 (26.7%) | 23/30 (76.7%) |
| Event | Obinutuzumab + Chlorambucil (GClb) | Chlorambucil (Clb) | Crossover Subjects: Obinutuzumab + Chlorambucil (GClb) |
|---|---|---|---|
| Infusion related reactionInjury, poisoning and procedural complications | 27/241 | 0/116 | 0/30 |
| Febrile neutropeniaBlood and lymphatic system disorders | 2/241 | 5/116 | 1/30 |
| PneumoniaInfections and infestations | 10/241 | 4/116 | 1/30 |
| SepsisInfections and infestations | 0/241 | 4/116 | 1/30 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 7/241 | 0/116 | 1/30 |
| IleusGastrointestinal disorders | 0/241 | 0/116 | 1/30 |
| GastroenteritisInfections and infestations | 0/241 | 0/116 | 1/30 |
| Bowen's diseaseNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/241 | 0/116 | 1/30 |
| Lung NeoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/241 | 0/116 | 1/30 |
| Metastatic neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/241 | 0/116 | 1/30 |
| Event | Obinutuzumab + Chlorambucil (GClb) | Chlorambucil (Clb) | Crossover Subjects: Obinutuzumab + Chlorambucil (GClb) |
|---|---|---|---|
| Infusion related reactionInjury, poisoning and procedural complications | 147/241 | 0/116 | 15/30 |
| NeutropeniaBlood and lymphatic system disorders | 99/241 | 21/116 | 12/30 |
| NauseaGastrointestinal disorders | 32/241 | 29/116 | 3/30 |
| ThrombocytopeniaBlood and lymphatic system disorders | 36/241 | 9/116 | 7/30 |
| LeukopeniaBlood and lymphatic system disorders | 17/241 | 0/116 | 5/30 |
| CoughRespiratory, thoracic and mediastinal disorders | 22/241 | 8/116 | 4/30 |
| VomitingGastrointestinal disorders | 13/241 | 14/116 | 0/30 |
| DiarrhoeaGastrointestinal disorders | 23/241 | 13/116 | 3/30 |
| AnaemiaBlood and lymphatic system disorders | 27/241 | 12/116 | 3/30 |
| PyrexiaGeneral disorders | 25/241 | 8/116 | 2/30 |
Baseline measures are based on the participants who were included in the Stage 1a analysis.
| Age, Customized(participants) | Obinutuzumab + Chlorambucil (GClb) | Chlorambucil (Clb) | Total |
|---|---|---|---|
| <65 years | 42 | 26 | 68 |
| >=65 years | 196 | 92 | 288 |
| Sex: Female, Male(Participants) | Obinutuzumab + Chlorambucil (GClb) | Chlorambucil (Clb) | Total |
|---|---|---|---|
| Female | 98 | 43 | 141 |
| Male | 140 | 75 | 215 |
Showing the first 100 of 262 sites across 26 countries. Choose a country and city above to see the rest.
Ran from Dec 2009 to primary completion in Jul 2012, 30 months.
Results were first posted in Apr 2014, 1 year 9 months after primary completion.
Of 57 industry-sponsored phase 3 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 73. This study's 30 months is below that.
Counting every sponsor, half of 83 studies reached it within 59 months; a quarter within 43 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Obinutuzumab
Leukemia, Lymphocytic, Chronic, B-Cell →